The CCDC167 Knockout 786-O Polyclonal Cells constitute a CRISPR/Cas9-mediated polyclonal knockout cell population wherein the CCDC167 gene has been disrupted to eliminate its expression. This polyclonal pool serves as a robust loss-of-function system, circumventing clonal variation and providing a genetically diverse model to study the functional significance of CCDC167 in renal cell carcinoma.
The parental 786-O cell line originates from a primary clear cell renal cell adenocarcinoma and is characterized by a von Hippel-Lindau (VHL) tumor suppressor gene mutation. This VHL-mutant background renders the cells constitutively active for hypoxia-inducible factor (HIF) signaling, making them an ideal model for clear cell renal cell carcinoma (ccRCC) research. Their epithelial morphology and well-documented signaling landscape facilitate detailed analyses of tumorigenic processes.
CCDC167 encodes a coiled-coil domain-containing protein with emerging roles in oncogenic signaling. Functional evidence suggests that CCDC167 may modulate cell proliferation and migration through its physical interaction with protein phosphatase 1 catalytic subunit alpha (PPP1CA). This interaction could influence the catalytic activity of PPP1CA and its holoenzyme complexes, thereby affecting the phosphorylation status of substrates involved in cell cycle regulation and actin cytoskeleton dynamics. The upstream activators and downstream effectors of CCDC167 remain poorly defined, highlighting the need for further investigation.
Within the 786-O context, which already displays dysregulated growth signaling due to VHL loss, the ablation of CCDC167 provides a powerful tool to dissect its specific contributions to ccRCC pathogenicity. Given the reported overexpression of CCDC167 in several cancers, this polyclonal knockout model allows researchers to assess its role in proliferation, migration, and potential interaction with the PP1 phosphatase network. The polyclonal nature of the knockout population better recapitulates the genetic heterogeneity of tumors compared to clonal derivatives.
These polyclonal knockout cells are amenable to a wide range of downstream applications. Researchers can perform western blotting to verify CCDC167 knockout and probe alterations in downstream signaling, employ MTT or BrdU incorporation assays to measure cell proliferation, and conduct transwell migration or invasion assays to evaluate metastatic propensity. Co-immunoprecipitation studies can confirm the CCDC167-PPP1CA interaction, and immunofluorescence staining can reveal changes in cytoskeletal organization. For additional details or ordering assistance, please contact Ascent Research.
